Efficacy and safety of baclofen for treatment of alcohol dependence: an updated meta-analysis and meta-regression study (Record no. 18368)

000 -LEADER
fixed length control field a
003 - CONTROL NUMBER IDENTIFIER
control field OSt
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20221130101333.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 221130b xxu||||| |||| 00| 0 eng d
040 ## - CATALOGING SOURCE
Original cataloging agency AIKTC-KRRC
Transcribing agency AIKTC-KRRC
100 ## - MAIN ENTRY--PERSONAL NAME
9 (RLIN) 8509
Author Phimarn, W.
245 ## - TITLE STATEMENT
Title Efficacy and safety of baclofen for treatment of alcohol dependence: an updated meta-analysis and meta-regression study
250 ## - EDITION STATEMENT
Volume, Issue number Vol.84(1), Jan-Feb
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Place of publication, distribution, etc. Mumbai
Name of publisher, distributor, etc. Indian Journal of Pharmaceutical Science
Year 2022
300 ## - PHYSICAL DESCRIPTION
Pagination 137-149p.
520 ## - SUMMARY, ETC.
Summary, etc. Baclofen is increasingly used for alcohol dependence treatment but its use remains controversial. Therefore,
this study aimed to assess the efficacy and safety of baclofen use on alcohol dependence. This is systematic
review and meta-analysis of randomized controlled trials. PubMed, Science Direct, Scopus and Thai
databases were systematically searched. Randomized controlled trials investigating efficacy and safety of
baclofen on alcohol dependence were included. Study selection, data extraction and quality assessment
were performed independently by two reviewers. The clinical therapeutic efficacy and adverse events of
baclofen were assessed and were pooled using a random-effects model. Heterogeneity was assessed by
I 2 and chi-squared test. Sixteen studies with 1539 alcohol dependence patients were included. Baclofen
increased risk of abstinence (risk ratio=1.32; 95 % confidence interval: 1.12, 1.55; p=0.0006) and abstinence
duration (standard mean difference=1.07 d (95 % confidence interval: 0.13, 2.01; p=0.04) significantly.
Moreover, baclofen significantly decreased heavy drinking days (standard mean difference=-1.14 d; 95 %
confidence interval:-1.95, -0.34; p=0.007). However, there were no significant effects on times to relapse,
craving and number of alcohol drinks. No serious adverse event associated with baclofen was reported
during treatments. The meta-regression found baclofen dose was significantly associated with craving.
This meta-analysis indicated that baclofen treatment in alcohol dependence patients is associated with
better outcomes in risk of abstinence, abstinence duration and heavy drinking days. However, larger well-
designed studies are required to confirm these conclusions.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
9 (RLIN) 4639
Topical term or geographic name entry element PHARMACEUTICS
700 ## - ADDED ENTRY--PERSONAL NAME
9 (RLIN) 19279
Co-Author Chamnanjit, P.
773 0# - HOST ITEM ENTRY
Title Indian journal of pharmaceutical sciences
Place, publisher, and date of publication New Delhi
856 ## - ELECTRONIC LOCATION AND ACCESS
URL https://www.ijpsonline.com/articles/efficacy-and-safety-of-baclofen-for-treatment-of-alcohol-dependence-an-updated-metaanalysis-and-metaregression-study.pdf
Link text Click here
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme
Koha item type Articles Abstract Database
Holdings
Withdrawn status Lost status Source of classification or shelving scheme Damaged status Not for loan Permanent Location Current Location Shelving location Date acquired Barcode Date last seen Price effective from Koha item type
          School of Pharmacy School of Pharmacy Archieval Section 2022-11-30 2022-2247 2022-11-30 2022-11-30 Articles Abstract Database
Unique Visitors hit counter Total Page Views free counter
Implemented and Maintained by AIKTC-KRRC (Central Library).
For any Suggestions/Query Contact to library or Email: librarian@aiktc.ac.in | Ph:+91 22 27481247
Website/OPAC best viewed in Mozilla Browser in 1366X768 Resolution.

Powered by Koha